Kistler Tiffany Companies LLC Sells 3,000 Shares of West Pharmaceutical Services Inc. (WST)

Kistler Tiffany Companies LLC cut its holdings in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 5.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,418 shares of the medical instruments supplier’s stock after selling 3,000 shares during the period. West Pharmaceutical Services comprises approximately 2.3% of Kistler Tiffany Companies LLC’s holdings, making the stock its 9th largest holding. Kistler Tiffany Companies LLC owned approximately 0.07% of West Pharmaceutical Services worth $4,844,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in WST. Riverbridge Partners LLC boosted its position in West Pharmaceutical Services by 37.8% in the 3rd quarter. Riverbridge Partners LLC now owns 647,980 shares of the medical instruments supplier’s stock valued at $80,006,000 after buying an additional 177,637 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of West Pharmaceutical Services by 614.6% in the 3rd quarter. Marshall Wace LLP now owns 99,369 shares of the medical instruments supplier’s stock valued at $12,269,000 after purchasing an additional 85,464 shares during the period. Macquarie Group Ltd. lifted its stake in shares of West Pharmaceutical Services by 0.7% in the 2nd quarter. Macquarie Group Ltd. now owns 107,213 shares of the medical instruments supplier’s stock valued at $10,645,000 after purchasing an additional 786 shares during the period. Prudential Financial Inc. lifted its stake in shares of West Pharmaceutical Services by 145.2% in the 3rd quarter. Prudential Financial Inc. now owns 218,492 shares of the medical instruments supplier’s stock valued at $26,977,000 after purchasing an additional 129,400 shares during the period. Finally, Intermede Investment Partners Ltd lifted its stake in shares of West Pharmaceutical Services by 4.1% in the 3rd quarter. Intermede Investment Partners Ltd now owns 253,071 shares of the medical instruments supplier’s stock valued at $31,247,000 after purchasing an additional 10,078 shares during the period. Institutional investors and hedge funds own 92.50% of the company’s stock.

A number of research firms have recently weighed in on WST. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Saturday. ValuEngine raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th.

WST stock traded down $0.75 during trading hours on Monday, reaching $103.08. 7,582 shares of the stock were exchanged, compared to its average volume of 376,313. The stock has a market cap of $7.69 billion, a PE ratio of 37.03, a price-to-earnings-growth ratio of 3.68 and a beta of 1.21. The company has a current ratio of 2.94, a quick ratio of 2.23 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services Inc. has a 12 month low of $82.74 and a 12 month high of $125.09.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.06. The firm had revenue of $431.70 million during the quarter, compared to analysts’ expectations of $427.55 million. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. On average, analysts forecast that West Pharmaceutical Services Inc. will post 2.83 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 6th. Shareholders of record on Wednesday, January 23rd will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Tuesday, January 22nd. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.58%.

COPYRIGHT VIOLATION WARNING: “Kistler Tiffany Companies LLC Sells 3,000 Shares of West Pharmaceutical Services Inc. (WST)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.com-unik.info/2019/01/14/kistler-tiffany-companies-llc-sells-3000-shares-of-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Read More: What are defining characteristics of a correction?

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit